Phase II trial of S-1 monotherapy as adjuvant chemotherapy in triple negative breast cancer patients who did not achieve pathological complete response after neoadjuvant chemotherapy
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2018
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Oct 2018 Status changed from active, no longer recruiting to completed.
- 03 Mar 2017 Planned End Date changed from 1 Aug 2014 to 1 Feb 2019.
- 06 Aug 2013 Planned End Date changed from 1 Aug 2012 to 1 Aug 2014 as reported by University Hospital Medical Information Network - Japan.